Explore the rapidly evolving field of #CardioOncology at the Memorial Sloan Kettering Cancer Center #MSKCardioOncCME on May 2-3. Director, Jennifer Liu, offers an exclusive glimpse into this year's exciting program. Learn more or register at bit.ly/MSKCardioOnc20…

#CardioTwitter Dipti Gupta MD, MPH

Starting a cardio-oncology center of excellence can be overwhelming - but it doesn't have to be. A 🧵 of resources to get you started.

Support Wilfried Mullens

In a new Review, Bonnie Ky and colleagues discuss the bidirectional relationship between #cardiovascular disease and #cancer , including shared risk factors and pathophysiological mechanisms: rdcu.be/dElDh

Riabilitazione #cardiooncologica step by step. Sul nuovo numero del #GIC position #paper
ANMCO & ITACARE by Bisceglia et al con la guida di Oliva
giornaledicardiologia.it/archivio/4244/…

Interatrial Shunt Falls Short in Sham-Controlled #RELIEVE -HF

📍Overall, there was no significant difference in the primary effectiveness endpoint between the two study arms (weighted win ratio 0.86; P = 0.20).

#HFrEF had fewer adverse CV events, whereas patients with #HFpEF

Thrilled to be part of this of this terrific ExEcho symposium. Jan Verwerft Alexander Vd Bruaene Guido Claessen Frederik H. Verbrugge

Welcome, #PCHF Alumni '26🌎🌍🌏The Postgraduate Course in #HeartFailure continues to empower #global cardiovascular health with a proficient network of > 320 international alumni ready to tackle #HeartFailure 🫀heartfailure.com

University of Zurich Unispital_USZ Radiologie USZ

Our #cardioonc pilot data in JACC Journals (t.ly/k9BYr) shows it may potentially be safe to stop #HeartFailure meds in pts with asymptomatic mild #cardiotoxicity & now improved #LVEF . Now time for the #RCT data! dineshpmcc Husam Abdel-Qadir Kaz Negishi@Cardiologist/ Heart Mafia Charlotte Manisty Ben Dowsing

A CMR-derived model, including mass morphology and tissue characterization, showed excellent accuracy, superior to echocardiography, in predicting CMs malignancy, with prognostic implications Pasquale Paolisso Luca Bergamaschi @belmontemarta Alberto Foà ahajrnls.org/3IMbKBX

Moderate/severe TR raises #HeartFailure & #CVdeath risk in #HFrEF patients, highlighting the need for TR management. This study also shows that omecamtiv mecarbil’s effectiveness remains unaffected by TR severity. bit.ly/4cc8kGk

#JACCHF Marianna Adamo Marco Metra

The central role of the cardiologist in the decision-making and management of Anderson Fabry disease!

academic.oup.com/eurheartj/adva…

#EHJ #cardiotwitter #Fabry #Disease @ESC_journals European Society of Cardiology

#HeartFailure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence

academic.oup.com/eurheartj/adva…

#CardioEd #CardioOncology #EHJ European Society of Cardiology Journals European Society of Cardiology

Dear #cardiooncology colleagues,
We are planning a RCT to test less frequent cardiac imaging during HER2 targeted therapy for #breastcancer . We want your input re study design. It will be of great value.
Pls consider completing a 5-min questionnaire at forms.office.com/r/RdgvbnhcG4

Most viewed JAMA Cardiology article:

In this study, results showed that in patients with HFpEF and chronotropic incompetence, β-blocker cessation may be particularly beneficial in patients with smaller end-systolic left ventricular volume.

ja.ma/4bHqSOc

#EchoMasterRome started yesterday!
✅ knowledge
✅teaching
✅friendship
A great start, thanks to prof Antonella Lombardo for making it possible!💫💫💫
1 module faculty
Gabriella Locorotondo Nicolas Merke Corrado Fiore Rosa Lillo francesca graziani_FG 🌟